Reprieve

New Study Published in JACC: Heart Failure Reveals that Despite Significant Efforts to Improve Acute Heart Failure Treatment Over the Past 20 Years, Management Remains Unchanged

Retrieved on: 
Thursday, May 2, 2024
Research, Medical Devices, Hospitals, Clinical Trials, Health Technology, Cardiology, Biotechnology, Managed Care, Health, Science, Stanford University, Mortality, Heart, Fluid, Heart failure, ADHF, American College, Clinical trial, GDMT, AUC, Hospital, Weight loss, Partnership, Area studies, Nursing, Patient, Reprieve, Physician, Acute, Circulatory system, Kaiser Permanente, Hyperkalemia, SDOH, HF, Division, Hypotension, Pharmaceutical industry

Decongestion remains a central goal of inpatient management, but contemporary decongestion practices and associated weight loss are not well described.

Key Points: 
  • Decongestion remains a central goal of inpatient management, but contemporary decongestion practices and associated weight loss are not well described.
  • In the TREAT-AHF study, the distribution of inpatient body weight change was similar to those reported from ADHERE nearly two decades ago.
  • Reprieve is partnering with industry-leading heart failure researchers and Truveta to understand and advance acute heart failure patient outcomes.
  • The clinical evidence from the TREAT-HF study demonstrates that heart failure decongestion management has not substantially changed in 20 years,” said Mark Pacyna, chief executive officer of Reprieve Cardiovascular.

Reprieve Cardiovascular Emerges from Stealth Mode after $42 Million Series A Financing to Bring Intelligent Fluid Management to Heart Failure Patients

Retrieved on: 
Tuesday, February 20, 2024
Health, Medical Devices, Health Technology, General Health, Clinical Trials, Cardiology, Biotechnology, Volume overload, Pacyna, Diuretic, Physician, Acute decompensated heart failure, Leg, Standard of care, Heart failure, ADHF, FASTR, Reprieve, Fatigue, Patient, Medtronic, Circulatory system, Pharmaceutical industry

Reprieve Cardiovascular , Inc., a development stage company focused on pioneering an intelligent automated diuretic and fluid management approach for acute decompensated heart failure (ADHF) treatment, today announced it has raised a total of $42 million in series A financing.

Key Points: 
  • Reprieve Cardiovascular , Inc., a development stage company focused on pioneering an intelligent automated diuretic and fluid management approach for acute decompensated heart failure (ADHF) treatment, today announced it has raised a total of $42 million in series A financing.
  • The total round was co-led by Lightstone Ventures and Sante Ventures and joined by Deerfield Management, Genesis Capital, and Arboretum Ventures.
  • The funding will advance the Company’s clinical and development programs, including the ongoing FASTR trial and its upcoming pivotal trial.
  • Pacyna continued, “Reprieve Cardiovascular is bringing intelligent decongestion management to heart failure patients.

Truveta announces availability of millions of echocardiogram reports to advance cardiovascular research

Retrieved on: 
Wednesday, November 8, 2023
ADHF, Peripheral artery disease, Moyamoya disease, MD, Organization, Transthoracic echocardiogram, Health, Journal, Pulmonary embolism, TLM, Risk, Pulmonary hypertension, Stenosis, Reprieve, Acute decompensated heart failure, EHR, Society, AI, Patient, Boston Scientific, PAD, Heart failure, Pharmaceutical industry

BELLEVUE, Wash., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Today Truveta announced the availability of more than 56.6 million clinical observations from more than 2.7 million echocardiogram reports from more than 1.7 million de-identified patients, making it the market leader in real-world data to advance cardiovascular research at scale.

Key Points: 
  • BELLEVUE, Wash., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Today Truveta announced the availability of more than 56.6 million clinical observations from more than 2.7 million echocardiogram reports from more than 1.7 million de-identified patients, making it the market leader in real-world data to advance cardiovascular research at scale.
  • New peer-reviewed research using Truveta Data was published recently in the Journal of the Society for Cardiovascular Angiography and Interventions (JSCAI) comparing two treatments for pulmonary embolism and identifying risk for adverse events like major bleeding.
  • Existing methods, such as relying on registry data or physician referrals, have limitations in scope and timeliness, hindering large-scale research.
  • The availability of these data has the potential to propel cardiovascular research forward in ways never before possible, opening new horizons of discovery and innovation to improve patient care and outcomes and save lives."

Regenesis Achieves FDA Clearance for the New Reprieve by Regenesis™ Device

Retrieved on: 
Tuesday, August 22, 2023
Pain management, Pain, Diabetic neuropathy, Regenesis, Food and Drug Administration, FDA, Health, Reprieve, Food, Medical device, Pharmaceutical industry

SCOTTSDALE, Ariz., Aug. 22, 2023 /PRNewswire/ -- Regenesis Biomedical, Inc., a medical devic­­e company focused on safe, non-drug, pain management, announced today commercialization of the new Reprieve by Regenesis™ device (Reprieve). Reprieve is the only home-use shortwave diathermy device on the market and is based on Regenesis' core pulsed electromagnetic energy platform.

Key Points: 
  • SCOTTSDALE, Ariz., Aug. 22, 2023 /PRNewswire/ -- Regenesis Biomedical, Inc., a medical devic­­e company focused on safe, non-drug, pain management, announced today commercialization of the new Reprieve by Regenesis™ device (Reprieve).
  • Reprieve is the only home-use shortwave diathermy device on the market and is based on Regenesis' core pulsed electromagnetic energy platform.
  • "In alignment with our Vision to improve health for a longer, more active, and fulfilling life, we are pleased to announce we received Food and Drug Administration (FDA) clearance for our new Reprieve by Regenesis device," said Tom Eisiminger, President and CEO.
  • Because our new device has a two-treatment applicator option, we are expanding our efforts into the podiatric space with a focus on the treatment of pain associated with diabetic neuropathy."

Mental Health and Substance Use Awareness Takes Center Stage During NYFW at Break Free

Retrieved on: 
Friday, February 18, 2022
Internet, Break Free, Doctor of Philosophy, Pasadena Recovery Center, Awareness, Mental health, Particle-size distribution, Hair, Bed, Industry, Pharmaceutical industry, Nightclub, Reprieve

NEW YORK, Feb. 18, 2022 /PRNewswire/ -- Break Free NYFW held its maiden showcase on Monday, February 14th featuring designers Wu-Sah, Jacquline City Apparel, Love Disorder, Adorn Your Clothes, and LadyCat.

Key Points: 
  • NEW YORK, Feb. 18, 2022 /PRNewswire/ -- Break Free NYFW held its maiden showcase on Monday, February 14th featuring designers Wu-Sah, Jacquline City Apparel, Love Disorder, Adorn Your Clothes, and LadyCat.
  • These designers came together to raise awareness for the nonprofit organization, 10,000 Beds , which has a scholarship fund to assist those struggling with substance use disorders attend a rehabilitation center of their choice for treatment.
  • Break Free is the brainchild of Alexandra Nyman , the creative director of LadyCat and Editor-In-Chief of Soberocity.
  • As well as Gabi DeMartino, Demi Skipper of the Trade me Project, Firty Fashion, and Christine Handy.

Denver Filmmaker and Physician Dr. James Ehrlich Calls on Governor Polis to Test and Release Prison Inmates for Covid-19

Retrieved on: 
Thursday, June 11, 2020
Ehrlich, Reprieve, Bunn, Prison

It will profile an inmate David Bunn, age 60, and a colleague of Dr. Ehrlich while they were both healthcare teammates at Denver's Rose Medical Center in the 1980s.

Key Points: 
  • It will profile an inmate David Bunn, age 60, and a colleague of Dr. Ehrlich while they were both healthcare teammates at Denver's Rose Medical Center in the 1980s.
  • Bunn, a chronic asthmatic, is residing in close quarters with 1,600 other inmates.
  • In the past three weeks, Dr. Ehrlich has alerted state senators, several local and national journalists, and a U.S.
  • Civil rights attorney Andy McNulty states, "Governor Polis has the unfettered ability to temporarily reprieve prisoners from serving their sentences."